First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN

被引：0
|
作者：
Hou, X. [1 ]
Zhou, C. [2 ]
Wu, G. [3 ]
Lin, W. [4 ]
Xie, Z.
Zhang, H. [2 ,5 ,6 ]
Yi, J. [7 ]
Peng, Z. [8 ]
Yin, L. [8 ]
Ma, C. [8 ]
Chen, L. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] Meizhou Peoples Hosp, Huangtang Hosp, Meizhou, Peoples R China
[4] Shantou Univ, Canc Hosp, Med Coll, Shantou, Peoples R China
[5] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China
[6] Guangzhou Univ Chinese Med, Guangdong Hong Kong Macau Joint Lab Chinese Med &, Guangzhou, Peoples R China
[7] Guangzhou Red Cross Hosp, Guangzhou, Peoples R China
[8] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-squamous non-small-cell lung cancer; Brain metastases; Immunochemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-04
引用
收藏
页码：S318 / S318
页数：1
相关论文
共 50 条
  • [21] Potential Predictors of Sensitivity to Pemetrexed as First-line Chemotherapy for Patients with Advanced Non-Squamous NSCLCs
    Lu, Yan-Yan
    Huang, Xin-En
    Xu, Lin
    Liu, De-Gan
    Cao, Jie
    Wu, Xue-Yan
    Liu, Jin
    Xiang, Jin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (03) : 2005 - 2008
  • [22] Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC
    Wang, Bao-Xiao
    Ou, Wei
    Mao, Xiao-Yong
    Liu, Zui
    Wu, Hui-Qi
    Wang, Si-Yu
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2017, 160 : 96 - 100
  • [23] Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience
    Bose, Subhadeep
    Khaja, Mujtaba Syed
    Siva, Asha
    Wilson, Paula
    Grist, Helen
    Murukesh, Nishanth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial
    Li, Y. -S.
    Yang, J. -J.
    Yu, Q.
    Bu, Q.
    Lin, L.
    Ning, F.
    Wu, G.
    Lin, G.
    Zang, A.
    Ma, S.
    Zhou, C.
    Liu, A.
    Zhao, Y.
    Wang, C.
    Yao, Y.
    Han, G.
    Zhao, J.
    Pan, Y.
    Sun, H.
    Zheng, M. -M.
    Liu, S. -Y. M.
    Yan, H. -H.
    Tu, H. -Y.
    Zhou, Q.
    Lv, J.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S399 - S400
  • [25] First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC
    Wang, Lijie
    Gao, Ming
    Yang, Wenyu
    Wang, Chunyu
    Wang, Ting
    Jing, Fangfang
    Ma, Junxun
    Zhang, Fan
    Tao, Haitao
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Brain radiotherapy combined with camrelizumab and platinum-based chemotherapy as first-line treatment for advanced NSCLC with brain metastases: A multicenter, open-label, single-arm, phase II study
    Fan, Y.
    Xu, Y.
    Huang, Z.
    Xu, Y.
    Sheng, L.
    Li, H.
    Lu, H.
    Chen, K.
    Yu, S.
    Gong, L.
    Han, N.
    Xu, X.
    Qin, J.
    Xie, F.
    Hong, W.
    Huang, D.
    Chen, J.
    ANNALS OF ONCOLOGY, 2023, 34
  • [27] Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
    Ren, Shengxiang
    Chen, Jianhua
    Xu, Xingxiang
    Jiang, Tao
    Cheng, Ying
    Chen, Gongyan
    Pan, Yueyin
    Fang, Yong
    Wang, Qiming
    Huang, Yunchao
    Yao, Wenxiu
    Wang, Rui
    Li, Xingya
    Zhang, Wei
    Zhang, Yanjun
    Hu, Sheng
    Guo, Renhua
    Shi, Jianhua
    Wang, Zhiwu
    Cao, Peiguo
    Wang, Donglin
    Fang, Jian
    Luo, Hui
    Geng, Yi
    Xing, Chunyan
    Lv, Dongqing
    Zhang, Yiping
    Yu, Junyan
    Cang, Shundong
    Yang, Zeyu
    Shi, Wei
    Zou, Jianjun
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 544 - 557
  • [28] Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
    Laktionov, K.
    Smolin, A.
    Stroyakovskiy, D.
    Moiseenko, V.
    Dvorkin, M.
    Andabekov, T.
    Cheng, Y.
    Liu, B.
    Kozlov, V.
    Odintsova, S.
    Dvoretsky, S.
    Mochalova, A.
    Urda, M.
    Yi, T.
    Li, X.
    Laszlo, U.
    Mueller, V.
    Bogos, K.
    Fadeeva, N.
    Musaev, G.
    Liu, Q.
    Kirtbaya, D.
    Shi, J.
    Gladkov, O.
    Narimanov, M.
    Semiglazova, T.
    Khasanova, A.
    Chovanec, J.
    Andrasina, I
    Szabova, A.
    Rosinska, O.
    Sudekova, D.
    Zsolt, P. -s.
    Ran, F.
    Sun, M.
    Jiang, O.
    Chen, R.
    Zhao, E.
    Liu, C.
    Tan, W.
    Pirmagomedov, A.
    Poddubskaya, E.
    Kislov, N.
    Shumskaya, I.
    Sorokina, I.
    Zinkina-Orikhan, A.
    Linkova, Yu.
    Fogt, S.
    Liaptseva, D.
    Siliutina, A.
    EUROPEAN JOURNAL OF CANCER, 2025, 217
  • [29] Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction
    Peng, Zhi
    Wei, Jia
    Wang, Feng
    Ying, Jieer
    Deng, Yanhong
    Gu, Kangsheng
    Cheng, Ying
    Yuan, Xianglin
    Xiao, Juxiang
    Tai, Yanfei
    Wang, Linna
    Zou, Jianjun
    Zhang, Yanqiao
    Shen, Lin
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3069 - 3078
  • [30] First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
    Yang, Zhiguang
    Zhu, Yumei
    Xiang, Guiyuan
    Hua, Tiantian
    Ni, Jun
    Zhao, Jie
    Lu, Yun
    Wu, Yingyu
    Chang, Feng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1061 - 1067
12345